Genomadix Gets FDA 510(k) Clearance for PCR System, CYP2C19 Test
Canada's Genomadix, formerly known as Spartan Bioscience, expects to now commercialize the system and test in the US to guide therapy decisions.
In multiple presentations, researchers at ACC/WCC's annual meeting explored the impact of genotyping cardiac patients within a week of starting dual anti-platelet therapy.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.
Spartan Bioscience Taps Cardinal Health as US Distributor of CYP2C19 Genotyping Assay
The new distribution partnership is for the US acute care market where, until now, Spartan was selling directly.
Spartan Bioscience, Angiocare Ink Distribution Deal for CYP2C19 Test
Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.